

α -Mangostin: Anti-Inflammatory Activity and Metabolism by Human Cells

Fabiola Gutierrez-Orozco,[†] Chureeporn Chitchumroonchokchai,[‡] Gregory B. Lesinski,[§] Sunit Suksamrarn,^{||} and Mark L. Failla^{*,†,‡}

[†]Interdisciplinary Ph.D. Program in Nutrition, [‡]Human Nutrition Program, [§]Department of Internal Medicine, The Ohio State University, Columbus, Ohio 43210, United States

^{||}Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Srinakharinwirot University, Bangkok, Thailand

ABSTRACT: Information about the anti-inflammatory activity and metabolism of α -mangostin (α -MG), the most abundant xanthone in mangosteen fruit, in human cells is limited. On the basis of available literature, we hypothesized that α -MG will inhibit the secretion of pro-inflammatory mediators by control and activated macrophage-like THP-1, hepatic HepG2, enterocyte-like Caco-2, and colon HT-29 human cell lines, as well as primary human monocyte-derived macrophages (MDM), and that such activity would be influenced by the extent of metabolism of the xanthone. α -MG attenuated TNF- α and IL-8 secretion by the various cell lines but increased TNF- α output by both quiescent and LPS-treated MDM. The relative amounts of free and phase II metabolites of α -MG and other xanthones present in media 24 h after addition of α -MG was shown to vary by cell type and inflammatory insult. Increased transport of xanthones and their metabolites across Caco-2 cell monolayers suggests enhanced absorption during an inflammatory episode. The anti-inflammatory activities of xanthones and their metabolites in different tissues merit consideration.

KEYWORDS: α -mangostin, xanthones, mangosteen, inflammation, metabolism, human cells

INTRODUCTION

Garcinia mangostana is a tree native to Southeast Asia that produces a fruit referred to as mangosteen. The aril portion of mangosteen fruit has an acidic, sweet taste that is enjoyed by many, whereas extracts of the pericarp have been used in traditional medicine. The proposed health-promoting properties of pericarp from mangosteen have been associated with a family of compounds referred to as xanthones.¹ These hydrophobic compounds have a tricyclic aromatic ring system possessing various mixtures of isoprenyl, hydroxyl, and methoxyl substitutions.² α -Mangostin (α -MG, Figure 1) and




Figure 1. Structure of α -mangostin.

γ -mangostin (γ -MG) are the most abundant xanthones in the pericarp of mangosteen fruit.^{3,4} In vitro studies have consistently shown xanthones to possess antioxidant,^{5,6} antiproliferative,⁷ proapoptotic,^{8,9} antimicrobial,¹⁰ anti-inflammatory,^{11,12} and anticarcinogenic activities.^{8,9,13} Anti-inflammatory^{11,14–16} and anticarcinogenic^{17–19} activities have also been demonstrated in rodents. As a result of the aggressive marketing of health-promoting activities observed in cellular and rodent models, numerous supplements, beverages, and food products containing mangosteen fruit have become

available with sales of beverages alone in 2008 exceeding \$200 million in the United States.²⁰

In order for xanthones to exert their proposed health-promoting activities, these compounds or their active metabolites must be delivered to target tissues. We previously reported that α -MG and its phase II metabolites were transported across the basolateral membrane of Caco-2 human intestinal cells, suggesting that a portion of xanthones in mangosteen products likely were bioavailable.²¹ Indeed, low concentrations of xanthones and their phase II metabolites have been identified in the plasma and urine of healthy adults after consumption of mangosteen juice.^{22,23} Xanthones and phase II metabolites also have been detected in the plasma and liver of athymic Balb/c nu/nu mice fed an AIN-93G diet containing 900 mg of xanthones/kg,¹⁸ as well as in plasma from C57BL/6J mice orally dosed with α -MG.²⁴ Moreover, the presence of α -MG and other xanthones in the HT-29 human colon cell xenografts in mice fed the diet containing α -mangostin was associated with decreased tumor growth and reduced tumor expression of the mitogenic Wnt protein and antiapoptotic bcl-2 protein.¹⁸ These data suggest that xanthones and/or their metabolites are absorbed and delivered to various tissues, where they may be accumulated, further metabolized, and modulate cellular processes.

The antiproliferative and proapoptotic activities of xanthones have been demonstrated in numerous in vitro studies using

Received: January 29, 2013

Revised: March 28, 2013

Accepted: April 4, 2013

Published: April 4, 2013




Figure 2. The lack of stability of α -MG in basal media in cell-free dishes (panel A) was offset by addition of the xanthone solubilized in DMSO to media containing 10% FBS or by addition of the xanthone incorporated in Tween 40 to basal media (panel B). Data are mean \pm SD for $n = 3$ dishes with media.

rodent cell lines.^{7–9,11,12} However, the reported anti-inflammatory activity of xanthenes in cells of human origin has been limited to primary cultures of adipocytes²⁵ and the U937 macrophage-like cell line.²⁶ To the best of our knowledge, the uptake and metabolism of these compounds by cells of animal or human origin have not been examined with the exception of differentiated cultures of Caco-2 human intestinal cells.²¹ Similarly, the effect that the pro-inflammatory condition may have on the metabolism of α -MG has not been addressed.

Although it has been generally assumed that xanthenes are stable in cell culture media, many polyphenols degrade spontaneously in vitro and generate products such as hydrogen peroxide, which is known to induce transcriptional activity associated with the anti-inflammatory response.^{27,28} The first objective of the present study was to investigate the anti-inflammatory activity of α -MG in prototypical human immune cell types and in other human cells originating from tissues responsive to inflammatory insult. This initially required developing appropriate delivery systems to ensure the stability of the xanthone in the different culture media used for the proliferation and activities of the tested cell types. The second objective was to study the metabolism of this xanthone by these cell types maintained in normal and pro-inflammatory environments. To the best of our knowledge, this work is the first to systematically compare the anti-inflammatory activity of α -MG for human cells with various tissue origins, as well as the metabolism of this xanthone under normal and inflammatory conditions.

MATERIALS AND METHODS

Chemicals and Reagents. α -, γ -, and β -mangostins, 9-hydroxycalabaxanthone, gartanin, and garcinones D and E were purified (>98% as assessed by NMR spectroscopy and ESIMS) as described previously.^{3,5} All solvents (acetonitrile, ethyl acetate, acetic acid, *n*-butanol, 2-propanol) and water were HPLC grade from Fisher Scientific (Pittsburgh, PA). Cell culture reagents were from Sigma-Aldrich (St. Louis, MO) and Gibco (Grand Island, NY). IL-8 and TNF- α ELISA DuoSet Kits were purchased from R&D Systems (Minneapolis, MN). MCS-F was obtained from Peptotech, Inc. (Rocky Hill, NJ). Fluorochrome-conjugated anti-CD14 and anti-CD11b were purchased from BD Biosciences (San Jose, CA). Ficoll-Paque PLUS was obtained from GE Healthcare (Uppsala, Sweden). Transwell inserts and filters were from Millipore (Billerica, MA). All other reagents and materials were from Sigma-Aldrich.

Cell Cultures. The following human cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA) for use in this study: THP-1 (monocyte-like leukemia), HepG2 (hepatocellular carcinoma), Caco-2 HTB-37 (colorectal adenocarcinoma cells that spontaneously differentiate to enterocyte-like phenotype), and HT-29 (colorectal adenocarcinoma). Since α -MG has been reported to exert anti-inflammatory activity in murine RAW 264.7 macrophage-like cells,^{11,12} this cell line was included for comparison with the responses of the human cell types. HepG2 cells (passages 5–15), HT-29 cells (passages 135–139), and RAW 264.7 (unknown passage) were maintained as per ATCC recommendations and used for experiments 2 days after monolayers reached confluency. THP-1 monocyte cells (unknown passage) were differentiated to macrophage-like cells by treatment with 100 nM phorbol myristate acetate (PMA) for 48 h before initiating experiments. Caco-2 cells (passages 20–40) spontaneously differentiated to a phenotype resembling the intestinal epithelium by culturing by 21–25 day postconfluency as previously described.²⁹ Primary cultures of monocytes were prepared from buffy coats obtained from the American Red Cross (Columbus, OH). Mononuclear cells were separated by centrifugation through a Ficoll-Paque PLUS and further purified by the clumping method.³⁰ Monocytes were differentiated to macrophages by treatment with 50 ng/mL M-CSF for 6 days. Monocyte-derived macrophages (MDM) were 97% pure as estimated by flow cytometry after staining cells with anti-CD14 and anti-CD11b as cellular markers. All cultures were maintained at 37 °C in a humidified atmosphere of 95% air/5% CO₂.

Stability of α -MG during Incubation in the Cell Culture Environment. As many polyphenolic compounds spontaneously degrade in cell culture media,^{27,28} we first examined the stability of α -MG solubilized in DMSO and added to the various media lacking FBS. Stability was assessed by incubation in a cell free system for 24 h. Aliquots were collected at 0, 4, 8, and 24 h before extraction and analyzed as described below. Recovery of α -MG from all basal media decreased in proportion to duration of incubation in the absence of cells (Figure 2A). The extent of loss after 24 h ranged from 55 to 97%, depending on the composition of the medium. The calculated rate of α -MG loss per hour during the 24 h incubation was 2.7, 4.0, 3.2, and 2.3% in RPMI, MEM, DMEM, and McCoy's 5A, respectively.

On the basis of the above observation, the influence of delivery vehicle and the presence of FBS in media were tested as possible stabilizers of α -MG during incubation in cell-free media. Dimethyl sulfoxide (DMSO), Tween 40, and FBS were used to prepare stock solutions of the xanthone for addition to media. A stock solution of α -MG was prepared in DMSO before dilution in MEM, DMEM, and RPMI media containing 10% FBS and filter sterilized (0.22 μ m pores). The final amount of DMSO in the test media was <0.03%. To prepare Tween 40 micelles containing α -MG, the compound was solubilized in acetonitrile and mixed with 20% Tween 40:80% acetone before

Table 1. Experimental Conditions for Assessing the Anti-Inflammatory Activity of α -Mangostin

cell type	delivery vehicle	IC ₅₀ (μ M)	α -MG pretreatment		pro-inflammatory stimulus		inflammatory marker
			μ M	h	insult (ng/mL)	h	
RAW 264.7	10% FBS	23	10	2	LPS ^a (5)	16	nitric oxide
THP-1	10% FBS	23	10	4	LPS (0.1)	4	IL-8
MDM	10% FBS	>12	4.5	4	LPS (100)	10	TNF- α
HepG2	10% FBS	25	7	16	PMA ^b (50)	4	TNF- α
Caco-2	Tween 40	>80	15	4	IL-1 β (5)	16	IL-8 ^c
HT-29	Tween 40	180	10	1	LPS (100)	16	IL-8

^aLipopolysaccharide (LPS) from *Escherichia coli* 0111:B4. ^bPhorbol 12-myristate 13-acetate. ^cMeasured in basolateral medium.

evaporating the solvent under a stream of nitrogen gas. After addition of basal media (either DMEM or McCoy's 5A), the mixture was sonicated for 30 min to facilitate incorporation of the xanthone in the Tween micelles. Media were filtered (0.22 μ m pores) and further diluted to obtain indicated concentrations of the xanthone. The final content of Tween 40 in test media was <0.02%. FBS was also used as delivery vehicle by incubating pure α -MG with 100% FBS for 48 h at 37 °C in a shaking water bath (85 rpm). This stock solution was then filtered (0.22 μ m pores) and diluted 1:10 with RPMI 1640. The stability of α -MG during the 24 h incubation period was increased to 101 \pm 6% (p < 0.05) when DMSO containing the xanthone was added to media (RPMI 1640, MEM, and DMEM) with 10% (v/v) FBS. Similarly, recovery of α -MG from DMEM and McCoy's media without FBS after 24 h incubation was 110 \pm 3 and 108 \pm 4, respectively, when the xanthone was incorporated in Tween 40 micelles. The stability of α -MG was 95 \pm 8% after 24 h when the xanthone was added to 100% FBS that was diluted 1:10 (v/v) into RPMI 1640 (Figure 2B). Subsequently, α -MG solubilized in DMSO was delivered to medium containing 10% FBS for macrophage-like THP-1, macrophage-like RAW 264.7, and HepG2 cells, and α -MG was solubilized in Tween 40 micelles added to medium for enterocyte-like Caco-2 cells and HT-29 colonic cells. For MDM cells, α -MG was delivered in 100% FBS to a final concentration of 10% FBS in RPMI 1640 medium.

Cytotoxicity of α -MG. Cell cultures were exposed to increasing concentrations of α -MG to determine cytotoxicity. Viability of RAW 264.7, MDM, HepG2, and HT-29 was assessed after 24 h, whereas that of THP-1 and Caco-2 cells was determined after 8 and 4 h, respectively. Times of exposure matched those used in experiments addressing anti-inflammatory activity and metabolism described below. Examination of cell morphology by phase contrast microscopy and reduction of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] to formazan were used as indicators of cytotoxicity as this reaction is dependent on mitochondrial respiration.³¹

Anti-Inflammatory Activity of α -MG. The anti-inflammatory activity of α -MG was studied by measuring its inhibitory effects on the secretion of pro-inflammatory mediators. Preliminary studies were performed for each cell type to establish nontoxic concentrations and appropriate periods for preincubation with α -MG, as well as the concentrations and duration of exposure to pro-inflammatory stimuli. Cells were incubated in media containing concentrations of α -MG well below the IC₅₀ to determine the effect, if any, on responsiveness to pro-inflammatory insult. Experimental conditions for determining the anti-inflammatory activity of α -MG are presented in Table 1. As Caco-2 cells were grown on Transwell membrane inserts, α -MG was added to the apical compartment before addition of IL-1 β to the basolateral compartment. IL-8 was selected as biomarker of inflammation in Caco-2 and HT-29 cells given its essential role as a chemoattractant during intestinal inflammation.³² IL-8 also served as the marker for THP-1 macrophage-like cells as it is the predominant chemokine in supernatants of LPS-treated cells.³³ TNF- α is a key mediator of hepatic physiology and pathology, and its secretion was selected as the marker for PMA-stimulated HepG2 cells.³⁴ Because TNF- α secretion by tissue macrophages has been proposed as a key mediator of LPS-triggered septic shock, this inflammatory cytokine was selected as a marker in MDM cells.³⁵ Finally, medium nitrite concentration was used as a surrogate for the induction of iNOS (inducible nitric oxide synthase)

activity in RAW 264.7 cells. IL-8 and TNF- α were quantified by ELISA as instructed by the manufacturer. Nitrite concentration in medium was measured by the Griess reaction.³⁶

Cellular Uptake and Metabolism of α -MG. Cells were exposed to nontoxic concentrations of α -MG (5.2, 3.3, 7.7, 9.0, 12.0, and 8.5 μ M, for THP-1, MDM, RAW 264.7, HepG2, Caco-2, and HT-29 cells, respectively), using previously established delivery systems (Figure 2B) to ensure stability of the xanthone in culture. After 24 h, spent medium and cells were collected separately for analysis, except for RAW 264.7 cells, where both cells and medium were collected in the same tube, as some cells were nonadherent at confluency. For cultures with Caco-2 cells, medium with α -MG was added to the apical compartment, and medium from both the basolateral and apical compartments along with cell monolayer were collected separately for analysis. Spent medium and cells were extracted as previously described²¹ prior to reverse-phase high-performance liquid chromatography (RP-HPLC).³ Glucuronidated/sulfated metabolites of α -MG were determined as previously described.²¹ Identification and quantification of xanthenes was based on retention time, UV spectrum, and five-point standard curves using pure (>98%) α -, γ -, and β -mangostins; 9-hydroxycalabaxanthone; gartanin; and garcinones D and E. When pure compounds were not available, identification was made by comparison with the retention time and UV spectrum reported in the literature^{3,4} and the concentration estimated as α -MG equivalents. Peaks with a xanthone-like spectra (λ_{max} = 240–300 and 310–370 nm)⁴ that could not be matched to one of the standards were labeled as unknown.

Effect of Inflammation on Uptake and Metabolism. To study the effect of inflammatory conditions on the metabolism of α -MG, cells were exposed to the following inflammatory insults: 5 ng/mL LPS for THP-1 and RAW 264.7 cells, 100 ng/mL LPS for MDM, 10 ng/mL TNF- α for HepG2 cells, 5 ng/mL IL-1 β for Caco-2 cells, and 800 ng/mL LPS for HT-29. LPS was used at higher concentrations in cultures with THP-1 and HT-29 cells than those used for the anti-inflammatory experiments in order to ensure a robust pro-inflammatory state. Since HepG2 cells secrete TNF- α in response to PMA treatment, we used this cytokine to induce a pro-inflammatory state. After 4 h, media containing inflammatory stimuli were aspirated and cells washed with sterile PBS. Cultures were then incubated in medium containing α -MG at concentrations similar to those used in cultures under control conditions. Spent media and washed cells were collected after 24 h for analysis as above.

Statistical Analysis. The number of independent cultures tested per cell line for each experiment was \geq 5 and each experiment was repeated at least twice. Data are reported as mean \pm standard deviation (SD). For analysis, one-way ANOVA was performed followed by Tukey post hoc in order to determine differences between treatments. A p -value of less than 0.05 was considered statistically significant. Statistical analyses were performed using Minitab 16.2.2.

RESULTS

Anti-Inflammatory Activity of α -MG. α -MG was previously reported to exert an anti-inflammatory effect on murine RAW 264.7 macrophage-like cells.^{11,12} We initially




Figure 3. α -MG attenuates secretion of inflammatory mediators in activated human cell lines but exacerbates TNF- α secretion by LPS-treated cultures of human monocyte-derived macrophages (MDM). THP-1 and MDM cells were differentiated to macrophage-like phenotype and Caco-2 cells differentiated to an enterocyte-like phenotype. Data are mean \pm SD, for $n \geq 5$. Different letters above bars in a panel indicate significant differences at $p < 0.05$.

monitored the effect of treatment with α -MG on LPS-induced generation of nitric oxide (NO) in RAW 264.7 cultures for comparison with its effect on the response of various cell lines to pro-inflammatory insult. Exposure to LPS increased NO production 36-fold above that in control cultures. Concentrations of 1, 3, and 10 μ M α -MG inhibited LPS-induced production of NO by 50, 61 and 78%, respectively, significantly ($p < 0.05$) exceeding the extent of inhibition (30%) mediated by 200 μ M L-NAME, a widely used nonspecific inhibitor of iNOS (data not shown).

The effect of α -MG on the secretion of inflammatory mediators was dependent on human cell type and state of cellular activation (Figure 3). Pretreatment with α -MG significantly ($p < 0.05$) attenuated IL-8 secretion by activated macrophage-like THP-1 (Figure 3A), enterocyte-like Caco-2 (Figure 3D) and colonic HT-29 (Figure 3E) cells, and TNF- α secretion by PMA-activated HepG2 cells (Figure 3C). In contrast, pretreatment of MDM cells with α -MG increased LPS-stimulated secretion of TNF- α more than 50% (Figure 3B). When added to nonactivated cultures, α -MG also more than doubled basal secretion of TNF- α by MDM cells (Figure




Figure 4. Metabolism of α -MG in control and activated cell cultures. Data (mean \pm SD, $n \geq 5$) represent the amounts of free xanthenes and their glucuronidated/sulfated metabolites in medium and cells as a percentage of the initial amount of α -MG added to each culture. Dark bars represent free xanthenes and open bars indicate glucuronidated/sulfated metabolites. M: medium, C: cells, AM: apical medium, BM: basolateral medium. THP-1 and MDM cells were differentiated to macrophage-like cells and Caco-2 cells differentiated to an enterocyte-like phenotype. *Denotes statistically significant difference in free:conjugated ratio in activated cultures when compared to control cultures ($p < 0.05$).

3B) and IL-8 by HT-29 cells (Figure 3E), suggesting pro-inflammatory activity. Concentrations of α -MG as low as $0.7 \mu\text{M}$ also significantly ($p < 0.05$) increased TNF- α secretion by nonactivated MDM cells, although secretion of this cytokine was similar ($p > 0.05$) in LPS-treated cultures in the absence and presence of $0.7 \mu\text{M}$ α -MG (data not shown). Secretion of TNF- α in nonactivated cultures of HepG2 (Figure 3C) and secretion of IL-8 by nonactivated cultures of THP-1 (Figure 3A) and Caco-2 cells (Figure 3D) was not altered by the presence of α -MG in medium.

Cell Uptake and Metabolism of α -MG in Nonactivated Cultures. The reported anti-inflammatory activities of α -mangostin have assumed that the compound added to cell culture media or administered either by diet, gastric gavage, or

injection in preclinical models is responsible for the observed effects. Although limited, recent data suggests that dietary xanthenes are poorly absorbed.^{22–24,37} There is increased awareness that metabolites of “bioactive” dietary compounds often are the modulators of observed biological effects.^{38–40} Thus, we tested whether the observed anti-inflammatory activity of α -MG with the human cell lines was associated with the extent of its metabolism and profile of metabolites. Analysis of both media and cells indicated that α -MG was taken up by all tested cell lines. Glucuronide/sulfate conjugates of α -MG were identified in either both medium and cells or only in cells as described below. Xanthenes other than α -MG also were present despite their absence in medium added to cultures or in medium incubated for the same period of time in the absence

Table 2. Profile of Xanthenes in Media of Human Cell Cultures 24 h after Addition of α -MG^a

xanthone	THP-1 (pmol/dish)	HepG2 (pmol/dish)	Caco-2 (pmol/dish)	HT-29
α -MG (0 h)	33710 \pm 161	17834 \pm 115	20741 \pm 261	16517 \pm 373
α -MG (24 h)	13215 \pm 212	4688 \pm 354	9366 \pm 510	7512 \pm 410
garcinone C ^b	nd ^c	nd	339 \pm 41	273 \pm 80
garcinone D	nd	nd	nd	461 \pm 115
calabaxanthone derivative ^d	nd	173 \pm 17	nd	nd
9-hydroxycalabaxanthone	nd	44 \pm 10	80 \pm 7	nd
unknowns ^e	nd	1190 \pm 127	407 \pm 18	502 \pm 170

^aData are mean \pm SD for $n \geq 5$ cultures per cell type. ^bQuantity estimated by using a garcinone D calibration curve. ^cnd: not detected. ^dQuantity estimated by using a 9-hydroxycalabaxanthone calibration curve. ^eQuantities estimated as α -MG equivalents.

Table 3. Intracellular Profile of Xanthenes 24 h after Addition of α -MG to Control Cultures of Human Cell Types^a

xanthone	THP-1 (pmol/dish)	HepG2 (pmol/dish)	Caco-2 (pmol/dish)	HT-29
α -MG (0 h)	33710 \pm 161	17834 \pm 115	20741 \pm 261	16517 \pm 373
α -MG (24 h)	11439 \pm 995	9344 \pm 298	3000 \pm 551	807 \pm 178
garcinone D	66 \pm 2	nd ^b	nd	nd
calabaxanthone derivative ^c	nd	56 \pm 10	nd	nd
9-hydroxycalabaxanthone	nd	44 \pm 5	100 \pm 17	nd
unknowns ^d	355 \pm 57	732 \pm 174	170 \pm 12	nd

^aData are mean \pm SD for $n \geq 5$ cultures per cell type. ^bnd: not detected. ^cQuantity estimated by using a 9-hydroxycalabaxanthone calibration curve. ^dQuantity estimated as α -MG equivalents.

of cells. These xanthenes were detected in cultures of RAW 264.7, THP-1, HepG2, Caco-2, and HT-29 cells, but not in MDM.

Analysis of combined medium and cells revealed that RAW 264.7 murine macrophage-like cultures, our reference cell line, internalized and metabolized α -MG. Glucuronidated/sulfated conjugates (61 \pm 6%) were the primary metabolites, with free α -MG accounting for 18 \pm 3% of the initial concentration present in cultures. In addition, relatively low amounts of garcinone C and an unknown xanthone were detected. Recovery of α -MG was 80 \pm 6% after 24 h incubation.

Free xanthenes (20 \pm 4% of initial α -MG) and phase II conjugates (14 \pm 3%) were present in THP-1 cells, whereas only free xanthenes (40 \pm 1%) were present in spent medium (Figure 4A). Garcinone D and three unknown xanthenes also were detected in the cells (Table 3). Recovery of xanthenes after 24 h incubation was 75 \pm 6% of the amount of α -MG added to cultures. Only free xanthenes also were detected in spent medium from MDM and HepG2 cultures and accounted for 57 \pm 4% and 36 \pm 2% of initial amounts of α -MG, respectively. Both free and glucuronidated/sulfated conjugates of α -MG were present in MDM cells (22 \pm 5% and 20 \pm 10% of total, respectively) (Figure 4B) and HepG2 cells (27 \pm 3% and 29 \pm 3% of total, respectively) (Figure 4C). Other xanthenes including 9-hydroxycalabaxanthone, a calabaxanthone-like compound, and several unknown xanthenes also were detected in spent medium and cells in HepG2 cultures (Tables 2 and 3), but not in cultures of MDM cells. Recovery of α -MG equivalents added to cultures of MDM and HepG2 was 99 \pm 12% and 91 \pm 4%, respectively.

Apical medium containing 12 μ M α -MG was added to cultures of differentiated Caco-2 cells on Transwell inserts and incubated for 24 h. Xanthenes in apical medium, basolateral medium, and cells accounted for 47 \pm 3% (35 \pm 1% free and 11 \pm 2% conjugates), 3 \pm 0.3% (0.8 \pm 0.1% free and 1.7 \pm 0.3% conjugated), and 16 \pm 3% (6 \pm 0.6% free and 10 \pm 3%

conjugated) of the initial amount of α -mangostin, respectively. In addition, garcinone C, 9-hydroxycalabaxanthone, and two unknown xanthenes were detected in Caco-2 cultures (Tables 2 and 3). Recovery of xanthenes represented approximately 65% of the amount of α -MG added to the cultures, suggesting the presence of other unknown metabolites (Figure 4D).

HT-29 cells metabolized the majority of α -MG to phase II conjugates that were present in both medium and cells, accounting for 42 \pm 3% and 5 \pm 1%, respectively, of α -MG added to the cultures. Garcinones C and D and an unknown xanthone also were detected in spent medium (Table 2). Free xanthenes accounted for 7 \pm 2% of initial amount of α -MG in the medium, but only traces of these nonconjugated xanthenes were detected in cells (Figure 4E). Recovery of α -MG after incubation in cultures of HT-29 cells was only 54 \pm 4%.

The above data generally show that α -MG was transported and metabolized to phase II compounds by all human cell types and converted into other xanthenes by the transformed human cell lines but not by the primary cultures of MDM cells.

Uptake and Metabolism of α -MG in Response to Inflammatory Insult. As α -MG was shown to attenuate secretion of IL-8 and TNF- α by the activated cell lines, we next examined whether the metabolism of this xanthone was altered in a pro-inflammatory environment. Cultures were exposed to cell-specific inflammatory stimuli before addition of α -MG to media. After 24 h, media and cells were analyzed for xanthenes and their metabolites. The total amounts of xanthenes in media and cells were similar to that in nonactivated cultures (Figure 4). However, the inflammatory environment was associated with an increased intracellular ratio of free to conjugated xanthenes in THP-1 (Figure 4A), HepG2 (Figure 4C), and Caco-2 cells (Figure 4D), as well as in medium of HT-29 cultures (Figure 4E) and apical medium in Caco-2 cell cultures ($p < 0.05$). In contrast, the amount of xanthenes and the ratio of conjugated to free xanthenes transported into the basolateral compartment by Caco-2 cells were increased by treatment with

IL-1 β ($p < 0.05$) (Figure 4D). The ratio of free to conjugated xanthenes in RAW 264.7 cultures also was increased by LPS treatment (data not shown). Treatment of MDM cells with LPS did not significantly alter the relative amounts of free xanthenes and phase II metabolites of xanthenes either in medium or intracellularly (Figure 4B).

DISCUSSION

The goal of this study was to examine the *in vitro* anti-inflammatory activity and metabolism of α -MG in cells of human origin. Stability of α -MG was maintained by delivering the xanthone into media containing FBS or by solubilizing the xanthone in Tween 40 micelles for addition to serum-free media. Noncytotoxic concentrations of α -MG attenuated secretion of IL-8 and TNF- α by the various human cell lines. Influx and metabolism of α -MG to phase II metabolites and/or other xanthone products occurred with all cell lines. The extent of metabolism and types of products depended on cell type. In marked contrast with the results from the various cell lines, α -MG stimulated TNF- α secretion in both control and activated primary cultures of human MDM cells, and only glucuronidated/sulfated metabolites were detected in these cells. The results suggest that metabolic conversion of α -MG to other xanthenes may be necessary for anti-inflammatory activity. As Caco-2 cells have been shown to take up and transport metabolites of α -MG across the basolateral membrane²¹ and metabolites of xanthenes were present in sera soon after ingesting mangosteen juice,²³ it is expected that peripheral tissues are exposed to both free and conjugated xanthenes.

Epidemiological evidence suggests that a diet rich in fruit and vegetables prevents or may delay onset of cardiovascular disease, diabetes, and cancer.^{41–44} These effects have been attributed, in part, to plant-derived polyphenolic compounds.⁴⁵ Xanthenes from mangosteen fruit, for instance, exhibit anti-inflammatory^{11,12} and anticarcinogenic^{8,9,13} activities *in vitro*. Consideration of the *in vitro* stability of phytochemicals when assessing bioactivities is often neglected, despite the fact that many polyphenolic compounds readily react with components of cell culture media to generate H₂O₂, quinones, and semiquinones capable of inducing alterations in cellular activities.^{27,28} As part of our preliminary analysis, we found that α -MG was unstable when introduced into different basal media in the commonly used DMSO vehicle. Previous cellular studies reporting the *in vitro* anti-inflammatory activity of α -MG bioactivities used DMSO to deliver the xanthone to medium.^{11,12} It is unclear if FBS was present, and the stability of α -MG in these studies was not reported. The report that addition of catalase to medium inhibited γ -mangostin-mediated apoptosis in human malignant glioma cells supports the likelihood that spontaneous degradation of xanthenes in medium can induce alterations in cellular activities.⁴⁶ Thus, our first goal was to stabilize α -MG in cell culture in order to test its *in vitro* anti-inflammatory activity and cellular metabolism. Previous investigators have used Tween 40 to solubilize and stabilize β -carotene⁴⁷ and fetal bovine serum for delivery of lycopene⁴⁸ to cultured cells. We found that degradation of α -MG in media was prevented by incorporating α -MG in Tween 40 micelles, in media containing FBS, and by direct addition to FBS prior to its dilution in media (Figure 2). As lipophilic compounds are incorporated into micelles during digestion before being transported into enterocytes, Tween 40 micelles were used to deliver α -MG to enterocyte-like Caco-2 cells and colonic HT-29 cells. Because liver and immune cells

are exposed to plasma components *in vivo*, fetal bovine serum was selected as the delivery vehicle for HepG2, THP-1, MDM, and RAW 264.7 cells.

Previous studies examining the anti-inflammatory activity of α -MG in human cells have been limited to primary adipocytes²⁵ and macrophage-like U937 lymphoma cells,²⁶ where α -MG decreased LPS-induced expression of inflammatory genes. As the focus of our study was the anti-inflammatory activity of α -MG, we selected the human immune macrophage-like THP-1 cell line and primary monocyte derived macrophages (MDM) from human peripheral blood for investigation. HepG2 cells were included in our study because hepatic epithelial cells synthesize and secrete greater amounts of cytokines and acute phase proteins in response to pro-inflammatory signals, and our lab has identified xanthenes and their metabolites in hepatic tissue of mice fed a diet containing 900 mg of α -MG/kg.¹⁸ Differentiated cultures of Caco-2 human intestinal cells possess enterocyte-like characteristics, including a variety of host defense activities such as antigen-processing and presentation and secretion of a battery of cytokines and chemokines in response to pro-inflammatory insult.⁴⁹ Furthermore, we recently reported that α -MG inhibits colon HT-29 tumorigenicity *in vitro* and *in vivo*.¹⁸ Thus, these two colonic cell lines also were included in the study. Finally, because α -MG has been reported to inhibit the LPS-induced synthesis of NO by murine RAW 264.7 macrophage-like cells,^{11,12} the metabolism of the xanthone by these cells was considered for comparison with that by the human cells.

Our results showed that the impact of α -MG on the human cell lines differed from that on the primary MDM. Treatment of activated THP-1, Caco-2, and HT-29 cells with α -MG inhibited IL-8 chemokine secretion by 30–40%. Similarly, α -MG attenuated TNF- α secretion by 22% in PMA-activated cultures of HepG2 cells. In contrast, α -MG enhanced TNF- α secretion by both quiescent and activated primary cultures of MDM. This stimulatory effect with quiescent cultures was observed even when the concentration of the xanthone was less than 1 μ M. This lower concentration is more in line with those we found in serum of healthy adults following ingestion of a mangosteen juice product²³ and in mice after oral administration of α -MG in cottonseed oil.²⁴ Possible explanations for different responses of the cell lines and the primary MDM cells to α -MG may include differences in phenotype, tissue origin, and metabolism by transformed versus normal cells. Our experimental design is limited by the selection of only two inflammatory markers, *viz.*, secretion of IL-8 and TNF- α , to assess the activity of α -MG. More detailed studies, and particularly *in vivo* studies, are needed to further characterize the pro- and anti-inflammatory effects of xanthenes. In this regard, increased concentrations of inflammatory cytokines IL-1 α and IL-1 β , as well as higher T helper cell frequency and increased levels of complement C3 and C4, were found after healthy human subjects consumed 59 mL of a blended juice product containing mangosteen for 30 days.⁵⁰ The possibility that the proposed health-promoting effects of dietary xanthenes are mediated by induction of an adaptive stress or “hormetic” response in nontransformed cells merits investigation,^{51,52} as does the possibility that xanthenes may be detrimental for some inflammatory disorders.

Although there is extensive literature demonstrating the health-promoting properties of phytochemicals *in vitro*, many of these compounds undergo extensive first-pass metabolism to glucuronidated, sulfated, and methylated conjugates *in vivo*. Although such metabolites are generally assumed to be

inactive,^{53,54} recent evidence suggests that phase II metabolites exert some of the activities attributed to their parent compounds.^{33–35,55} We previously reported the presence of glucuronidated/sulfated metabolites of α -MG as early as 1 h after incubation of cells with the xanthone.²¹ We also observed these metabolites in cultures of RAW 264.7 cells 8 h after addition of α -MG (data not shown). These observations suggest that metabolites and/or the parent compound α -MG may affect early events in signaling pathways involved in synthesis of pro-inflammatory mediators. The present results agree with our recent reports that Caco-2 cells,²¹ mice,^{18,24} and human subjects²³ metabolize α -MG to phase II products. In addition to phase II metabolites, other xanthenes such as garcinones C and D, 9-hydroxycalabaxanthone, a calabaxanthone derivative, and several unknown xanthone compounds were detected in our analysis with the human cell lines. Many of these identified metabolites of α -MG are also present in mangosteen pericarp, suggesting that mixtures of xanthenes may have greater efficacy than individual compounds. Furthermore, recovery of α -MG in cultures for several of the human cell types was incomplete, suggesting the presence of additional metabolites. It also is possible that we underestimated xanthone conjugates due to incomplete enzymatic hydrolysis by the mollusc preparation due to the nature and position of substitutions on the tricyclic aromatic compounds, binding of conjugated xanthenes to proteins, localization within organelles, and the presence of natural inhibitors.⁵⁶ More robust analyses are required to further characterize xanthone metabolism and the bioactivities of the various metabolites.

During an inflammatory insult, the ratio of free to conjugated xanthenes increased in THP-1, HepG2, and Caco-2 cells and in the media of HT-29 and Caco-2 cell cultures. LPS has been reported to increase intracellular and secreted β -glucuronidase activity in RAW 267.4 cells, causing enhanced hydrolysis of quercetin glucuronides.⁵⁷ Similarly, increased serum β -glucuronidase activity in LPS-treated rats was associated with an increase in deconjugation of luteolin glucuronide.⁵⁸ Glucuronidase activity was increased in media of LPS-activated THP-1 and RAW 264.7 cells (data not shown). These observations may explain the greater concentration of free xanthenes in cells and media when α -MG was added to activated cultures. Also, transport of xanthenes (mainly conjugates) across the Caco-2 monolayer was increased when cells were pretreated with IL-1 β , supporting the possibility that xanthenes may be more bioavailable during inflammatory episodes. The possible use of xanthenes as coadjuvants for the treatment of chronic inflammatory conditions merits consideration.

The results for the present investigation show that α -MG attenuates the secretion of pro-inflammatory mediators by activated human cell lines of diverse tissue origin. However, this xanthone stimulates the secretion of TNF- α by primary cultures of quiescent and activated monocyte-derived human macrophages. We also show that α -MG was transported into cells, where it undergoes phase II metabolism and other metabolic processes in a manner that is dependent on cell type and inflammatory status. We speculate that these metabolites may be immunomodulatory either by stabilizing the parent compound or by directly exerting anti- or pro-inflammatory activity. Finally, we also show that inflammatory conditions may alter cellular metabolism of α -MG and possibly increase its bioavailability.

AUTHOR INFORMATION

Corresponding Author

*E-mail: faila.3@osu.edu.

Funding

This research was partially funded by The Ohio State University Comprehensive Cancer Center/Molecular Carcinogenesis and Chemoprevention Program and Food Innovation Center. F.G-O was supported in part by CONACyT (Mexico) doctoral fellowship.

Notes

The authors declare no competing financial interest.

ABBREVIATIONS USED

α -MG, α -mangostin; MDM, monocyte-derived macrophages; LPS, lipopolysaccharide; RP-HPLC, reverse-phase high-performance liquid chromatography; MCS-F, macrophage colony stimulating factor; PMA, phorbol myristate acetate; LC-MS, liquid chromatography-mass spectroscopy; NMR, nuclear magnetic resonance; DMSO, dimethyl sulfoxide; FBS, fetal bovine serum; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide; NO, nitric oxide; iNOS, inducible nitric oxide synthase; PBS, phosphate-buffered saline; TNF- α , tumor necrosis factor- α ; IL- β , interleukin-1 β ; IL-8, interleukin-8.

REFERENCES

- (1) Pedraza-Chaverri, J.; Cárdenas-Rodríguez, N.; Orozco-Ibarra, M.; Pérez-Rojas, J. M. Medicinal properties of mangosteen (*Garcinia mangostana*). *Food Chem. Toxicol.* **2008**, *46*, 3227–39.
- (2) Obolskiy, D.; Pischel, I.; Siriwatanametanon, N.; Heinrich, M. *Garcinia mangostana* L.: A phytochemical and pharmacological review. *Phytother. Res.* **2009**, *23*, 1047–1065.
- (3) Chaivisuthangkura, A.; Malaikaew, Y.; Chaovanalikit, A.; Jaratrungratawae, A. Prenylated xanthone composition of *Garcinia mangostana* (mangosteen) fruit hull. *Chromatographia* **2009**, *69*, 315–318.
- (4) Walker, E. B. HPLC analysis of selected xanthenes in mangosteen fruit. *J. Sep. Sci.* **2007**, *30*, 1229–1234.
- (5) Jung, H. A.; Su, B. N.; Keller, W.; Mehta, R. G.; Kinghorn, A. D. Antioxidant xanthenes from pericarp of *Garcinia mangostana* (Mangosteen). *J. Agric. Food Chem.* **2006**, *54*, 2077–2082.
- (6) Williams, P.; Ongsakul, M.; Proudfoot, J.; Croft, K.; Beilin, L. Mangostin inhibits the oxidative modification of human low density lipoprotein. *Free Radical Res.* **1995**, *23*, 175–184.
- (7) Akao, Y.; Nakagawa, Y.; Iinuma, M.; Nozawa, Y. Anti-cancer effects of xanthenes from pericarps of mangosteen. *Int. J. Mol. Sci.* **2008**, *9*, 355–370.
- (8) Matsumoto, K.; Akao, Y.; Kobayashi, E.; Ohguchi, K.; Tanaka, T.; Iinuma, M.; Nozawa, Y. Induction of apoptosis by xanthenes from mangosteen in human leukemia cell lines. *J. Nat. Prod.* **2003**, *66*, 1124–1127.
- (9) Nakagawa, Y.; Iinuma, M.; Naoe, T.; Nozawa, Y.; Akao, Y. Characterized mechanism of α -mangostin-induced cell death: Caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells. *Bioorg. Med. Chem.* **2007**, *15*, 5620–5628.
- (10) Suksamrarn, S.; Suwannapoch, N.; Phakhodee, W.; Thanuhiranlert, J.; Ratananukul, P.; Chimnoi, N.; Suksamrarn, A. Antimycobacterial activity of prenylated xanthenes from the fruits of *Garcinia mangostana*. *Chem. Pharm. Bull.* **2003**, *51*, 857–859.
- (11) Chen, L. G.; Yang, L. L.; Wang, C. C. Anti-inflammatory activity of mangostins from *Garcinia mangostana*. *Food Chem. Toxicol.* **2008**, *46*, 688–693.
- (12) Tewtrakul, S.; Wattanapiromsakul, C.; Mahabusarakam, W. Effects of compounds from *Garcinia mangostana* on inflammatory mediators in RAW264.7 macrophage cells. *J. Ethnopharmacol.* **2009**, *121*, 379–382.

- (13) Lee, Y. B.; Ko, K. C.; Shi, M. D.; Liao, Y. C.; Chiang, T. A.; Wu, P. F.; Shih, Y. X.; Shih, Y. W. α -Mangostin, a novel dietary xanthone, suppresses TPA-mediated MMP-2 and MMP-9 expressions through the ERK signaling pathway in MCF-7 human breast adenocarcinoma cells. *J. Food Sci.* **2010**, *75*, H13–23.
- (14) Shankaranarayan, D.; Gopalak, C.; Kameswaran, L. Pharmacological profile of mangostin and its derivatives. *Arch. Int. Pharmacodyn.* **1979**, *239*, 257–269.
- (15) Nakatani, K.; Yamakuni, T.; Kondo, N.; Arakawa, T.; Oosawa, K.; Shimura, S.; Inoue, H.; Ohizumi, Y. γ -Mangostin inhibits inhibitor- κ B kinase activity and decreases lipopolysaccharide-induced cyclooxygenase-2 gene expression in C6 rat glioma cells. *Mol. Pharmacol.* **2004**, *66*, 667–674.
- (16) Jang, H.; Kwon, O.; Oh, S.; Lee, H.; Ahn, K. Mangosteen xanthones mitigate ovalbumin-induced airway inflammation in a mouse model of asthma. *Food Chem. Toxicol.* **2012**, *50*, 4042–4050.
- (17) Shan, T.; Ma, Q.; Guo, K.; Liu, J.; Wang, F.; Wu, E. Xanthones from mangosteen extracts as natural chemopreventive agents: Potential anticancer drugs. *Curr. Mol. Med.* **2011**, *11*, 666–677.
- (18) Chitchumroonchokchai, C.; Thomas-Ahner, J.; Li, J.; Riedl, K. M.; Nontakham, J.; Suksumrarn, S.; Clinton, S. K.; Kinghorn, A. D.; Failla, M. L. Anti-tumorigenicity of dietary α -mangostin in a HT-29 colon cell xenograft model and the tissue distribution of xanthones and their phase II metabolites. *Mol. Nutr. Food Res.* **2013**, *57*, 203–211.
- (19) Johnson, J. J.; Petiwala, S. M.; Syed, D. N.; Rasmussen, J. T.; Adhami, V. M.; Sliddiqui, I. A.; Kohl, A. M.; Mukhtar, H. α -Mangostin, a xanthone from mangosteen fruit, promotes cell cycle arrest in prostate cancer and decreases xenograft tumor growth. *Carcinogenesis* **2012**, *33*, 413–419.
- (20) Sloan, E. W. Getting ahead of the curve: Phytochemicals. *Nutraceutical World* **2010**, *13*, 16–17.
- (21) Bumrungpert, A.; Kalpravidh, R.; Suksumrarn, S.; Chaivisuthangkura, A.; Chitchumroonchokchai, C.; Failla, M. L. Bioaccessibility, biotransformation, and transport of α -mangostin from *Garcinia mangostana* (Mangosteen) using simulated digestion and Caco-2 human intestinal cells. *Mol. Nutr. Food Res.* **2009**, *53*, S54–S61.
- (22) Kondo, M.; Zhang, L.; Hongping, J.; Kou, Y.; Ou, B. Bioavailability and antioxidant effects of a xanthone-rich mangosteen (*Garcinia mangostana*) products in humans. *J. Agric. Food Chem.* **2009**, *57*, 8788–8792.
- (23) Chitchumroonchokchai, C.; Riedl, K. M.; Suksumrarn, S.; Clinton, S. K.; Kinghorn, D. A.; Failla, M. L. Xanthones in mangosteen juice are absorbed and partially conjugated by healthy adults. *J. Nutr.* **2012**, *142*, 675–680.
- (24) Ramaiya, A.; Li, G.; Petiwala, S. M.; Johnson, J. J. Single dose oral pharmacokinetic profile of α -mangostin in mice. *Curr. Drug Targets* **2012**, *13*, 1698–1704.
- (25) Bumrungpert, A.; Kalpravidh, R. W.; Chitchumroonchokchai, C.; Chuang, C.; West, T.; Kennedy, A.; McIntosh, M. Xanthones from mangosteen prevent lipopolysaccharide-mediated inflammation and insulin resistance in primary cultures of human adipocytes. *J. Nutr.* **2009**, *139*, 1185–1191.
- (26) Bumrungpert, A.; Kalpravidh, R. W.; Chuang, C.; Overman, A.; Martinez, K.; Kennedy, A.; McIntosh, M. Xanthones from mangosteen inhibit inflammation in human macrophages and in human adipocytes exposed to macrophage-conditioned media. *J. Nutr.* **2010**, *140*, 842–847.
- (27) Halliwell, B. The wanderings of a free radical. *Free Radical Biol. Med.* **2009**, *46*, 531–542.
- (28) Long, L. H.; Hoi, A.; Halliwell, B. Instability of, and generation of hydrogen peroxide by, phenolic compounds in cell culture media. *Arch. Biochem. Biophys.* **2010**, *501*, 162–169.
- (29) Chitchumroonchokchai, C.; Schwartz, S. J.; Failla, M. L. Assessment of lutein bioavailability from meals and a supplement using simulated digestion and Caco-2 human intestinal cells. *J. Nutr.* **2004**, *134*, 2280–2286.
- (30) Shen, L.; Guyre, P. M.; Ball, E. D.; Fanger, M. W. Glucocorticoid enhances gamma interferon effects on human monocyte antigen expression and ADCC. *Clin. Exp. Immunol.* **1986**, *65*, 387–395.
- (31) Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J. Immunol. Methods* **1983**, *65*, 55–63.
- (32) Schuerer-Maly, C. C.; Eckman, L.; Kagnoff, M. F.; Falco, M. T.; Maly, F. E. Colonic epithelial cell lines as a source of interleukin-8: Stimulation by inflammatory cytokines and bacterial lipopolysaccharide. *Immunol.* **1994**, *81*, 85–91.
- (33) Chanput, W.; Mes, J.; Vreeburg, R. M. V.; Savelkoul, H. F. J.; Wichers, H. J. Transcription profiles of LPS-stimulated THP-1 monocytes and macrophages: A tool to study inflammation modulating effects of food derived compounds. *Food Funct.* **2010**, *1*, 254–261.
- (34) Bauer, I.; Al Sarraj, J.; Vinson, C.; Larsen, R.; Thiel, G. Interleukin-1 β and tetradecanoylphorbol acetate-induced biosynthesis of tumor necrosis factor α in human hepatoma cells involves the transcription factors ATF2 and c-Jun and stress-activated protein kinases. *J. Cell Biochem.* **2007**, *100*, 242–255.
- (35) Xaus, J.; Comalada, M.; Vallerod, A. F.; Lloberas, J.; Lopez-Soriano, F.; Argiles, J. M.; Bogdan, C.; Celada, A. LPS induces apoptosis in macrophages mostly through the autocrine production of TNF- α . *Blood* **2000**, *95*, 3823–3831.
- (36) Wang, C. C.; Lai, J. E.; Chen, L. G.; Yen, K. Y.; Yang, L. L. Inducible nitric oxide synthase inhibitor of Chinese herbs part II: Naturally occurring furanocoumarins. *Bioorg. Med. Chem.* **2000**, *8*, 2701–2707.
- (37) Li, L.; Brunner, I.; Han, A.; Hamburger, M.; Kinghorn, A. D.; Frye, R.; Butterweck, V. Pharmacokinetics of α -mangostin in rats after intravenous and oral application. *Mol. Nutr. Food Res.* **2011**, *55*, S67–74.
- (38) Terao, J.; Murota, K.; Kawai, Y. Conjugated quercetin glucuronides as bioactive metabolites and precursors of aglycone in vivo. *Food Funct.* **2011**, *2*, 11–17.
- (39) Li, S.; Sang, S.; Pan, M.; Lai, C.; Lo, C.; Yang, C.; Ho, C. Anti-inflammatory property of urinary metabolites of nobiletin in the mouse. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 5177–5181.
- (40) Williamson, G.; Barron, D.; Shimoi, K.; Terao, J. In vitro biological properties of flavonoid conjugates found in vivo. *Free Radical Res.* **2005**, *39*, 457–469.
- (41) Hung, H.; Joshipura, K.; Jiang, R.; Hu, F.; Hunter, D.; Smith-Warner, S.; Colditz, G.; Rosner, B.; Spiegelman, D.; Willett, W. Fruit and vegetable intake and risk of major chronic disease. *J. Natl. Cancer Inst.* **2004**, *96*, 1577–1584.
- (42) Riboli, E.; Norat, T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. *Am. J. Clin. Nutr.* **2003**, *78*, S59–S69S.
- (43) Carter, P.; Gray, L.; Troughton, J.; Khunti, K.; Davies, M. Fruit and vegetable intake and incidence of type 2 diabetes mellitus: Systematic review and meta-analysis. *Br. Med. J.* **2010**, *341*, 4229–4236.
- (44) Dauchet, L.; Amouyel, P.; Hercberg, S.; Dallongeville, J. Fruit and vegetable consumption and risk of coronary heart disease: A meta-analysis of cohort studies. *J. Nutr.* **2006**, *136*, 2588–2593.
- (45) Soto-Vaca, A.; Gutierrez, A.; Losso, J. N.; Xu, Z.; Finley, J. W. Evolution of phenolic compounds from color and flavor problems to health benefits. *J. Agric. Food Chem.* **2012**, *60*, 6658–6677.
- (46) Chang, H.; Huang, W.; Chen, H.; Yang, L. Apoptotic effects of γ -mangostin from the fruit hull of *Garcinia mangostana* on human malignant glioma cells. *Molecules* **2010**, *15*, 8953–8966.
- (47) During, A.; Hussain, M. M.; Morel, D. W.; Harrison, E. H. Carotenoid uptake and secretion by Caco-2 cells: β -Carotene isomer selectively and carotenoid interactions. *J. Lipid Res.* **2002**, *43*, 1086–1095.
- (48) Lin, C.; Huang, C.; Hu, M. The use of fetal bovine serum as delivery vehicle to improve the uptake and stability of lycopene in cell culture studies. *Br. J. Nutr.* **2007**, *98*, 226–232.
- (49) Van de Walle, J.; Hendrickx, A.; Romier, B.; Larondelle, Y.; Schneider, Y. Inflammatory parameters in Caco-2 cells: Effect of

stimuli nature, concentration, combination and cell differentiation. *Toxicol. In Vitro* **2010**, *24*, 1441–1449.

(50) Tang, Y.; Li, P.; Kondo, M.; Ji, H.; Kou, Y.; Ou, B. Effect of a mangosteen dietary supplement on human immune function: A randomized double-blind-controlled trial. *J. Med. Food* **2009**, *12*, 755–763.

(51) Siow, R. C.; Mann, G. E. Dietary isoflavones and vascular protection: Activation of cellular antioxidant defenses by SERMs or hormesis? *Mol. Aspects Med.* **2010**, *31*, 468–77.

(52) Speciale, A.; Chirafisi, J.; Saija, A.; Cimino, F. Nutritional antioxidants and adaptive cell responses: An update. *Curr. Mol. Med.* **2011**, *9*, 770–89.

(53) Spencer, J.; Abd-el-Mohsen, M.; Rice-Evans, C. Cellular uptake and metabolism of flavonoids and their metabolites: Implications for their bioactivity. *Arch. Biochem. Biophys.* **2004**, *423*, 148–161.

(54) Lotito, S.; Zhang, W.; Yang, C.; Crozier, A.; Frei, B. Metabolic conversion of dietary flavonoids alters their anti-inflammatory and antioxidant properties. *Free Radical Biol. Med.* **2011**, *51*, 454–463.

(55) Larrosa, M.; González-Sarriás, A.; Yáñez-Gascón, M.; Selma, M.; Azorín-Ortuño, M.; Toti, S.; Tomás-Barberán, F.; Dolaro, P.; Espín, J. Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. *J. Nutr. Biochem.* **2010**, *21*, 717–725.

(56) Gu, L.; Laly, M.; Chang, H. C.; Prior, R. L.; Fang, N.; Ronis, M. J. J.; Badger, T. M. Isoflavones conjugates are underestimated in tissues using enzymatic hydrolysis. *J. Agric. Food Chem.* **2005**, *53*, 6858–6863.

(57) Kawai, Y.; Nishikawa, T.; Shiba, Y.; Saito, S.; Murota, K.; Shibata, N.; Kobayashi, M.; Kanayama, M.; Uchida, K.; Terao, J. Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: Implication in the anti-atherosclerotic mechanism of dietary flavonoids. *J. Biol. Chem.* **2008**, *283*, 9424–34.

(58) Shimoi, K.; Saka, N.; Nozawa, R.; Sato, I.; Amano, T.; Nakayama, T.; Kinae, N. Deglucuronidation of a flavonoid, luteolin monoglucuronide, during inflammation. *Drug Metab. Dispos.* **2001**, *29*, 1521–1524.